Origins of Cognigenics:

Cognigenics was originally co-founded by John Mee and Dr. Dean Radin. When John Mee read Dean Radin’s first book, Conscious Universe, in 1998, he found a scientific framework for understanding consciousness experiences he had in the 1960s which transcended space and time.  This book posits that consciousness has both local and non-local characteristics, and that non-local consciousness by definition has no location in space or time.  This conceptual framing encouraged John to examine his experiences scientifically.
 

Early research:

Besides applying the ideas of quantum non-locality to consciousness, Conscious Universe introduces a “bimodal” causation model of reality, which proposes that brain activity interacts with consciousness through neurology (bottom-up causation), and that consciousness can also influence brain activity (top-down causation). This model provides an insightful entry point into understanding the mind/matter interface.
 

After reading Electrophysiology of the Neuron by David McCormick and John Huguenard (Oxford University Press, 1999), John decided to examine top-down causation from an electrical engineering standpoint. Using McCormick’s descriptions of the micro-level electromagnetic waves which flow through neurons, he researched the relationship between non-local consciousness and physical neurology from 2000 until 2013. Meanwhile, Dean was continuing to refine his theories of extraordinary states of consciousness, publishing his second book, Entangled Minds, in 2008.
 

Cognitive neuroengineering:

Dean’s third book, Supernormal (Deepak Chopra Books, 2013) presents evidence that meditation increases psi abilities (ESP). Psi abilities are characteristic of non-local consciousness. Among other effects, meditation is known to lower brainwave activity down into the lower-frequency alpha and theta states. Meditators in these states who demonstrated increased psi abilities provided evidence that increased non-local consciousness (which has no wavelength) is correlated with reduced brainwave activity (which has wavelength).
 

After reading Supernormal in 2013, John contacted Dean to request his mentorship in developing a new branch of cognitive science based on the two pillars of quantum non-locality and bimodal causation originally described in Conscious Universe. Dean agreed, and the two men began collaborating on a theory for explaining the mind/matter interface to provide a scientific basis for enhancing human cognition. They reasoned that because higher states of consciousness and cognitive ability are likely to have a greater non-local component, and because non-local consciousness has no wavelength, then states of expanded awareness and cognition should be correlated with reduced brainwave activity, as Supernormal implies.
 

A subsequent literature search revealed a large body of scientific evidence indicating that conscious attention and cognitive capacity expand when brainwave activity is attenuated. Hundreds of other scientific experiments show that slower frequencies of brain activity are also correlated with reduced stress, as documented in John's 2015 manuscript, Cognitive Engineering.  Despite some technical errors, the manuscript managed to point their thinking in the right direction of downregulating neuronal excitability to enhance cognition.
 

Practical application:  

In 2016, John set about learning the best ways to use the genetic editing tool, CRISPR, to lower brainwave activity toward the more desirable alpha and theta brainwave states. With Dean’s help, he developed a cognitive neuroengineering strategy for optimizing brainwave patterns. The method alters a neuron’s electrical properties by slightly changing its structure with gene editing, thereby re-shaping the micro-level electromagnetic waves which flow through it. 
 

In 2018, John filed the initial patents on genetic engineering methods for producing sustainable human cognitive enhancement, and later that year, John and Dean formalized their business partnership.  Shortly thereafter, the two men filed a patent on novel methods for treating neurological conditions and improving human cognition by dynamically delivering gene therapies to targeted brain regions. They then added a third co-founder, Dr. Barry Linder, an MD with experience starting up biotech companies and running clinical trials.
 

Drawing upon Dean’s extensive professional network, the company expanded its leadership team, raised angel and venture funding, and completed preclinical research conclusively demonstrating its technology.  Cognigenics is now poised to transform mental health in the Genetic Age.  As illustrated below, the company's scientific discoveries have spawned not just a new technology, but the basis for a new industry.